Aurinia Pharmaceuticals (AUPH) Stock Rating Lowered by BidaskClub
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.
Several other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. ValuEngine raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 16th. Two research analysts have rated the stock with a sell rating, two have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $13.58.
AUPH opened at $6.27 on Friday. The firm has a market cap of $573.02 million, a PE ratio of -6.82 and a beta of 1.38. Aurinia Pharmaceuticals has a fifty-two week low of $5.01 and a fifty-two week high of $7.85.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Further Reading: What impact do institutional investors have on markets?
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.